{"id":"https://openalex.org/W2496670484","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20501","title":"Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.","display_name":"Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.","publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2496670484","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20501","mag":"2496670484"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.e20501","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20501","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20501","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100632072","display_name":"Yi-Long Lung Cancer Wu","orcid":"https://orcid.org/0000-0002-3611-0258","observed_orcids":["https://orcid.org/0000-0002-3611-0258"]},"institutions":[{"id":"https://openalex.org/I2799425052","display_name":"Guangdong General Hospital","ror":"https://ror.org/03jpekd50","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2799425052"]},{"id":"https://openalex.org/I4210145693","display_name":"Guangdong Academy of Medical Sciences","ror":"https://ror.org/0432p8t34","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210145693"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yi-Long Wu","raw_affiliation_strings":["Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China;","institution_ids":["https://openalex.org/I2799425052","https://openalex.org/I4210145693"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032293215","display_name":"Ross Andrew Soo","orcid":"https://orcid.org/0000-0002-3053-3997","observed_orcids":["https://orcid.org/0000-0002-3053-3997"]},"institutions":[{"id":"https://openalex.org/I4210103786","display_name":"National University Cancer Institute, Singapore","ror":"https://ror.org/025yypj46","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596","https://openalex.org/I4210103786","https://openalex.org/I4210150261"]},{"id":"https://openalex.org/I4210150261","display_name":"National University Health System","ror":"https://ror.org/05tjjsh18","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596","https://openalex.org/I4210150261"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Ross A. Soo","raw_affiliation_strings":["National University Cancer Institute, National University Health System, Singapore, Singapore, Singapore;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National University Cancer Institute, National University Health System, Singapore, Singapore, Singapore;","institution_ids":["https://openalex.org/I4210103786","https://openalex.org/I4210150261"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100638261","display_name":"Dong\u2010Wan Kim","orcid":"https://orcid.org/0000-0001-5124-7132","observed_orcids":["https://orcid.org/0000-0001-5124-7132"]},"institutions":[{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Dong-Wan Kim","raw_affiliation_strings":["Seoul National University Hospital, Seoul, South Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seoul National University Hospital, Seoul, South Korea;","institution_ids":["https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"James Chih-Hsin Yang","raw_affiliation_strings":["National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084841849","display_name":"Uz M. Stammberger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uz M. Stammberger","raw_affiliation_strings":["Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100624709","display_name":"Wenfeng Chen","orcid":"https://orcid.org/0000-0001-5259-7214","observed_orcids":["https://orcid.org/0000-0001-5259-7214"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenfeng Chen","raw_affiliation_strings":["Merck Serono Pharmaceutical R&D Co., Ltd., Beijing, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Serono Pharmaceutical R&D Co., Ltd., Beijing, China;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005665121","display_name":"Andreas Johne","orcid":"https://orcid.org/0000-0003-2690-2857","observed_orcids":["https://orcid.org/0000-0003-2690-2857"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Andreas Johne","raw_affiliation_strings":["Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030107272","display_name":"Keunchil Park","orcid":"https://orcid.org/0000-0002-4846-7449","observed_orcids":["https://orcid.org/0000-0002-4846-7449"]},"institutions":[{"id":"https://openalex.org/I2802194831","display_name":"Samsung Medical Center","ror":"https://ror.org/05a15z872","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2250650973","https://openalex.org/I2802194831"]},{"id":"https://openalex.org/I848706","display_name":"Sungkyunkwan University","ror":"https://ror.org/04q78tk20","country_code":"KR","type":"education","lineage":["https://openalex.org/I848706"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Keunchil Park","raw_affiliation_strings":["Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;","institution_ids":["https://openalex.org/I2802194831","https://openalex.org/I848706"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"e20501","last_page":"e20501"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tepotinib","display_name":"tepotinib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.7139999866485596},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.9549999833106995},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9890000224113464},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6330000162124634},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.7820000052452087},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.746999979019165},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8209999799728394},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7229999899864197},{"id":"https://openalex.org/keywords/asian-patients","display_name":"Asian patients","score":0.8690000176429749},{"id":"https://openalex.org/keywords/egfr-inhibitor-resistance","display_name":"EGFR inhibitor resistance","score":0.7789999842643738},{"id":"https://openalex.org/keywords/c-met-inhibition","display_name":"c-Met inhibition","score":0.5519999861717224},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9110000133514404},{"id":"https://openalex.org/keywords/hyperglycemia","display_name":"hyperglycemia","score":0.9710000157356262},{"id":"https://openalex.org/keywords/partial-response","display_name":"partial response","score":0.4519999921321869},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.7839999794960022}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9331766366958618},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7944722175598145},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.7224912643432617},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6789246797561646},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5521466135978699},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4588213264942169},{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.4310316741466522},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.39370253682136536},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.3218778669834137},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.30815017223358154},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2510976195335388},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.19090044498443604},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.e20501","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20501","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20501","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2587835256","https://openalex.org/W2890379622","https://openalex.org/W2474440166","https://openalex.org/W2587545056","https://openalex.org/W2514832332","https://openalex.org/W2898233073","https://openalex.org/W2900465001","https://openalex.org/W2955811607","https://openalex.org/W3029971508","https://openalex.org/W2905518326"],"abstract_inverted_index":{"e20501":[0],"Background:":[1],"Patients":[2],"(pts)":[3],"with":[4,7,40,60,104,117,136,194,230,236,263,273,307],"NSCLC":[5,276],"treated":[6,235],"EGFR":[8,19,77,82,170],"inhibitors":[9],"(EGFRi)":[10],"ultimately":[11],"develop":[12],"resistance,":[13],"often":[14],"through":[15],"c-Met":[16,21,38,87],"activation.":[17],"Dual":[18],"and":[20,43,86,144,182,209,291],"inhibition":[22],"is":[23,34,277,303],"therefore":[24],"a":[25,35,161],"rational":[26],"option":[27],"to":[28,128,315],"treat":[29],"c-Met+,":[30],"EGFRi-resistant":[31],"NSCLC.":[32,62],"Tepotinib":[33,257],"highly":[36],"selective":[37],"inhibitor":[39],"good":[41],"tolerability":[42],"promising":[44],"efficacy":[45],"against":[46],"solid":[47],"tumors.":[48,298],"This":[49],"phase":[50,300],"Ib":[51],"trial":[52,302,322],"examined":[53],"tepotinib":[54,111,133,183,268,316],"plus":[55],"gefitinib":[56,118,274,314,318],"in":[57,134,226,261,271,275],"Asian":[58,64],"pts":[59,149,239,306],"c-Met+/EGFR-mutant":[61],"Methods:":[63],"adults":[65],"were":[66,150,180,249],"eligible":[67],"if":[68],"they":[69],"had":[70,159,245],"locally":[71],"advanced/metastatic":[72],"NSCLC,":[73],"ECOG":[74],"PS":[75],"0-1,":[76],"mutation":[78],"confirmed":[79,187],"by":[80,91],"Therascreen":[81],"RGQ":[83],"PCR":[84],"(Qiagen),":[85],"positivity":[88],"as":[89,188,250],"determined":[90],"IHC":[92,231,288,296],"using":[93],"CONFIRM":[94],"anti-c-Met":[95],"mAb":[96],"(SP44;":[97],"Ventana/Roche).":[98],"A":[99,299],"3+3":[100],"design":[101],"was":[102,127,186,192,217,223,258],"used":[103],"expansion":[105],"at":[106],"the":[107,130,189,265],"RP2D.":[108,190],"Pts":[109,158],"received":[110,160,173],"300":[112],"or":[113,122,319],"500":[114,184,278],"mg/day":[115,120,185],"combined":[116],"250":[119],"(T300G250":[121],"T500G250).":[123],"The":[124,219],"primary":[125],"objective":[126],"determine":[129],"RP2D":[131,266],"of":[132,163,214,267,285],"combination":[135,262,272],"gefitinib;":[137,264],"secondary":[138],"objectives":[139],"included":[140],"pharmacokinetics":[141],"(PK),":[142],"safety,":[143],"antitumor":[145],"activity.":[146],"Results:":[147],"18":[148],"enrolled":[151],"(median":[152],"age":[153],"65":[154],"[41\u201378],":[155],"male":[156],"8).":[157],"median":[162],"2":[164],"(1\u20138)":[165],"prior":[166],"regimens":[167],"including":[168],"an":[169,282],"inhibitor.":[171],"6":[172],"T300G250,":[174],"12":[175],"T500G250.":[176],"No":[177,212],"dose-limiting":[178],"toxicities":[179],"observed,":[181],"T500G250":[191],"associated":[193],"treatment-related":[195],"grade":[196],"\u2265":[197],"3":[198],"increased":[199,204,283],"amylase":[200],"(n":[201],"=":[202,243],"2),":[203],"lipase":[205],"(2),":[206],"neutropenia":[207],"(1),":[208],"hyperglycemia":[210],"(1).":[211],"evidence":[213],"cumulative":[215],"toxicity":[216],"noted.":[218],"best":[220],"overall":[221],"response":[222,225,286],"partial":[224],"5/18":[227],"pts,":[228],"4":[229],"3+":[232,289],"tumors,":[233],"all":[234],"T500G250;":[237],"4/18":[238],"(IHC":[240],"2+,":[241],"n":[242],"3)":[244],"stable":[246],"disease.":[247],"PK":[248],"expected":[251],"based":[252],"on":[253],"historical":[254],"comparisons.":[255],"Conclusions:":[256],"well":[259],"tolerated":[260],"for":[269,287,295],"use":[270],"mg/kg/day.":[279],"Data":[280],"suggest":[281],"likelihood":[284],"tumors":[290,309],"prolonged":[292],"disease":[293],"stabilization":[294],"2+":[297],"II":[301],"randomizing":[304],"\u2248136":[305],"T790M\u2013/c-Met+":[308],"who":[310],"have":[311],"failed":[312],"first-line":[313],"+":[317],"cisplatin/pemetrexed.":[320],"Clinical":[321],"information:":[323],"NCT01982955.":[324]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":3}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-08-23T00:00:00"}